Yesterday, findings from the phase 2 biomarker trial, BIONIKK, were presented at the European Sociaety of Medical Oncology (ESMO) virtual congress. The study showed clinical evidence that biomarker-guided first-line therapy could be used to enrich responses in patients with metastatic clear cell renal cell carcinoma (RCC).

The trial included 154 patients treated with nivolumab or nivolumab/ipilimumab combination or a TKI. Tumour microenvironments were assessed. Patients whose tumours were considered “immune-low” and “immune-high” had poor outcomes with sunitinib. Conversely, patients who had “angio-high” and “normal-like” tumours were associated with favourable outcomes with sunitinib.

Further research is ongoing to look at the tumour genome, protein expression and circulating immune cells to determine a reliable biomarker for metastatic RCC.

Read more in OncLive Here